Stemline Therapeutics (STML) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies Cuts Price Target on Stemline Therapeutics (STML) Following 4Q Report
March 16, 2016 9:20 AM EDTJefferies maintained a Buy rating on Stemline Therapeutics (NASDAQ: STML), and cut the price target to $23.00 (from $30.00), following the company's 4Q. STML continues to evaluate SL-401. STML reported a 86% ORR in the potentially pivotal BPDCN trial last December at ASH. Management... More
Wedbush Remains Bullish as Stemline Therapeutics (STML) Reports In-Line 4Q - PT to $15
March 15, 2016 7:51 AM EDTWedbush maintained an Outperform rating on Stemline Therapeutics (NASDAQ: STML), and cut the price target to $15.00 (from $19.00), following the company's 4Q earnings report. STML reported a net loss of ($0.58) per share, in line with consensus' estimate of ($0.57). Management is expecting multiple clinical updates in 2016.... More
